IL10 expression is regulated by STAT3 (37) and a number of cytokines contribute to autocrine activation of STAT3 in TLR-activated CLL cells that would be blocked by ruxolitinib (Figure 2E). This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.